Pfizer’s Cannabinoid-Related Biotech Company Arena’s Q4 Net Loss Grows 27% YoY
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) revealed Wednesday financial results for the fourth quarter and full year ended Dec. 31, 2021.
Q4 Finanical HIghlights
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
HC Wainwright & Co. Downgrades Arena Pharmaceuticals to Neutral, Lowers Price Target to $100
HC Wainwright & Co. analyst Patrick Trucchio downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Buy to Neutral and lowers the price target from $120 to $100.
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral, Raises Price Target to $100
Cantor Fitzgerald analyst Alethia Young downgrades Arena Pharmaceuticals (NASDAQ:ARNA) from Overweight to Neutral and raises the price target from $93 to $100.
Benzinga’s Bulls And Bears Of The Past Week: Pfizer, Bank Of America, Beyond Meat, GameStop, AMC, Overstock And More
Benzinga has examined the prospects for many investor favorite stocks over the past week.
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
Below is a recap of the main news related to the cannabis industry and markets for the week of December 13, 2021.
Contents